Gabapentin in generalized seizures

Epilepsy Research
D W ChadwickE A Garofalo

Abstract

The efficacy of gabapentin (Neurontin), in generalized seizures was evaluated in this 14 week, double-blind, placebo-controlled, parallel-group, add-on, multicenter study. A total of 129 patients with refractory generalized seizures were randomized to receive either placebo or 1200 mg/day gabapentin as add-on therapy. Patients received their standard regimens of antiepileptic drugs (AEDs) during a 12 week baseline period, and gabapentin or placebo was added-on in the subsequent 14 week evaluation period. Results of both an intent-to-treat (ITT) and evaluable-patient analyses showed that gabapentin provided greater reduction in the frequency of generalized tonic-clonic seizures than did placebo; however, the differences between treatments were not statistically significant. Gabapentin did not affect the frequency of absence or myoclonic seizures. Adverse events were reported by 67% of gabapentin-treated patients and by 56% of placebo-treated patients. The most frequently occurring adverse events among patients receiving gabapentin were somnolence, fatigue, and dizziness. Gabapentin is well tolerated by patients with generalized seizures. The results of this study show a trend toward an effect of gabapentin in reducing the freque...Continue Reading

Citations

Apr 3, 1999·Medicinal Research Reviews·J S Bryans, D J Wustrow
Nov 30, 2000·Current Treatment Options in Neurology·K Murphy, N Delanty
Jan 15, 1999·Seizure : the Journal of the British Epilepsy Association·S BrownS Wallace
Jan 11, 2002·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies·H StefanO Steinlein
Aug 30, 2002·Epilepsia·Martin J BrodieUNKNOWN Gabapentin Study Group 945-212
Jul 15, 2000·Clinical Neuropharmacology·B F Bourgeois
Oct 26, 1999·Epilepsia·G L Morris
Apr 17, 2003·CNS Drugs·Charles L P DeckersY A Hekster
Mar 3, 2010·CNS Drugs·Dean P Sarco, Blaise F D Bourgeois
Mar 13, 2003·Mayo Clinic Proceedings·Randa G Jarrar, Jeffrey R Buchhalter
Oct 13, 2006·Pharmacology & Therapeutics·H Stefan, T J Feuerstein
May 7, 2014·Expert Opinion on Pharmacotherapy·Sylvain Rheims, Philippe Ryvlin
Mar 16, 2001·Expert Opinion on Pharmacotherapy·P H McCabe
Feb 12, 2008·Seizure : the Journal of the British Epilepsy Association·G ZaccaraM Cincotta
Feb 24, 2004·Journal of Pharmacological Sciences·Shinobu ShimizuHideki Ono
Jan 5, 2002·Neurological Research·J A Dougherty, D H Rhoney
May 10, 2017·Expert Opinion on Pharmacotherapy·Giangennaro CoppolaAlberto Verrotti
Feb 24, 2001·Journal of Child Neurology·J W Wheless
Jul 17, 2003·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Jarogniew J LuszczkiStanisław J Czuczwar
Feb 10, 2006·Expert Review of Neurotherapeutics·Leonie van PasselLawrence J Hirsch
Apr 29, 1998·Current Opinion in Neurology·J W Sander
Apr 17, 2007·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Mineo KuniharaAkio Arakawa

❮ Previous
Next ❯

Related Concepts

Related Feeds

Absence Epilepsy

Absence epilepsy is a common seizure disorder in children which can produce chronic psychosocial sequelae. Discover the latest research on absence epilepsies here.